Earl, H M, Hiller, L, Vallier, A-L, Loi, S, McAdam, K, Hughes-Davies, L, Harnett, A N, Ah-See, M-L, Simcock, R, Rea, D, Raj, S, Woodings, P, Harries, M, Howe, D, Raynes, K, Higgins, H B, Wilcox, M, Plummer, C, Mansi, J, Gounaris, I, Mahler-Araujo, B, Provenzano, E, Chhabra, A, Abraham, J E, Caldas, C, Hall, P S, McCabe, C, Hulme, C, Miles, D, M Wardley, A & Cameron, D A & Dunn, J A 2019, ' 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial ', The Lancet, vol. 393, no. 10191, pp. 2599-2612 . https://doi.org/10.1016/S0140-6736(19)30650-6 Lancet (London, England)
Lancet Oncology, 19, 12, pp. 1680-1687 Obstetrical and Gynecological Survey, 74(3), 156-158. Lippincott Williams and Wilkins MRC CHORUS study investigators 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', The Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7 Vergote, I, Coens, C, Nankivell, M, Kristensen, G B, Parmar, M K B, Ehlen, T, Jayson, G C, Johnson, N, Swart, A M, Verheijen, R, McCluggage, W G, Perren, T, Panici, P B, Kenter, G, Casado, A, Mendiola, C, Stuart, G, Reed, N S & Kehoe, S 2019, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: Pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials ', Obstetrical and Gynecological Survey, vol. 74, no. 3, pp. 156-158 . https://doi.org/10.1097/01.ogx.0000554460.78765.59 Jayson, G 2018, ' Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. ', Lancet Oncology, vol. 19, no. 12, pp. 1680-1687 . https://doi.org/10.1016/S1470-2045(18)30566-7 Lancet Oncology, 19, 1680-1687 The Lancet Oncology, 19(12), 1680-1687. Lancet Publishing Group